| Autor: |
Frechette KM; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Breen WG; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Brown PD; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Sener UT; Department of Neuro-Oncology, Mayo Clinic, Rochester, MN 55905, USA., Webb LM; Department of Neuro-Oncology, Mayo Clinic, Rochester, MN 55905, USA., Routman DM; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Laack NN; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Mahajan A; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Lehrer EJ; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA. |
| Abstrakt: |
Leptomeningeal disease (LMD) is a devastating sequelae of metastatic spread that affects approximately 5% of cancer patients. The incidence of LMD is increasing due to advancements in systemic therapy and enhanced detection methods. The purpose of this review is to provide a detailed overview of the evidence in the detection, prognostication, and treatment of LMD. A comprehensive literature search of PUBMED was conducted to identify articles reporting on LMD including existing data and ongoing clinical trials. We found a wide array of treatment options available for LMD including chemotherapy, targeted agents, and immunotherapy as well as several choices for radiotherapy including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and craniospinal irradiation (CSI). Despite treatment, the prognosis for patients with LMD is dismal, typically 2-4 months on average. Novel therapies and combination approaches are actively under investigation with the aim of improving outcomes and quality of life for patients with LMD. Recent prospective data on the use of proton CSI for patients with LMD have demonstrated its potential survival benefit with follow-up investigations underway. There is a need for validated metrics to predict prognosis and improve patient selection for patients with LMD in order to optimize treatment approaches. |
